Bachem Holding AG stock (CH0012530207): peptide specialist in focus after latest business update

Bachem Holding AG remains in the spotlight after its recent 2025 annual report and business update highlighted ongoing investments in capacity and peptide innovation. What this means for the Swiss biotech supplier’s stock and its relevance for US-focused investors.

Bachem Holding AG, a Swiss specialist for peptides and oligonucleotides used in pharmaceuticals, has drawn renewed investor attention following the publication of its 2025 annual report and business update in March 2026, which detailed revenue trends, profitability and major capacity projects according to Bachem financial reporting as of 03/12/2026. While the company continues to invest heavily in new production sites to support long?term growth, management also emphasized disciplined cost control and a focus on high?value custom manufacturing contracts in its latest communication to investors, as outlined in Bachem investor news as of 03/12/2026.

As of: 05/24/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Life sciences, pharmaceutical ingredients
• Headquarters/country: Bubendorf, Switzerland
• Core markets: Europe, North America and Asia-Pacific pharma and biotech customers
• Key revenue drivers: Custom manufacturing of peptides and oligonucleotides, generics portfolio, development services
• Home exchange/listing venue: SIX Swiss Exchange (ticker: BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem Holding AG positions itself as a full?service provider for peptide and oligonucleotide active pharmaceutical ingredients. The company develops and manufactures complex molecules on behalf of pharmaceutical and biotechnology customers, serving both clinical development projects and commercialized drugs, according to company descriptions in its corporate profile presented in 2025 on its website, as summarized in Bachem company profile as of 11/15/2025. Its offering spans early?stage R&D support, scale?up to large?scale production and a portfolio of catalog products used for research and development.

The business model centers on long?term relationships with drug developers that rely on Bachem’s specialized production capabilities. This includes stringent quality standards and regulatory compliance for active pharmaceutical ingredients supplied to global markets, with multiple manufacturing sites in Switzerland, Germany and the United States described in the 2024 sustainability and corporate responsibility report published in April 2025, according to Bachem sustainability report as of 04/18/2025. By combining process development expertise and industrial?scale facilities, Bachem aims to support customers over the entire lifecycle of a drug.

A second pillar of the model is a generic active ingredient and catalog business. Here Bachem offers standardized peptide APIs and research?grade products that are ordered repeatedly by generic drug manufacturers and research institutions worldwide, as described in its product overview in late 2025 on the company website, according to Bachem products and services overview as of 10/30/2025. This recurring revenue stream complements the more project?based custom manufacturing activity and may help to smooth demand over time, although individual product lifecycles and competitive pressures can still lead to fluctuations.

Main revenue and product drivers for Bachem Holding AG

In its 2025 annual report, covering the financial year 2025 and released in March 2026, Bachem reported that custom manufacturing of peptides and oligonucleotides remained the largest contributor to sales, with revenues in this segment growing compared with the prior year driven by demand for complex peptide APIs for metabolic and oncology indications, according to Bachem financial reporting as of 03/12/2026. Management highlighted a solid project pipeline, including late?stage development and commercial supply contracts, although exact customer names often remain undisclosed because of confidentiality agreements.

The company also noted that its generics and catalog business contributed meaningfully to total revenue, but performance was mixed due to pricing pressure and product?specific demand trends, as described in the same 2025 annual report published in March 2026, according to Bachem investor news as of 03/12/2026. Nevertheless, the breadth of the portfolio across therapeutic areas enables Bachem to benefit from the ongoing shift towards peptide?based drugs in fields such as diabetes, obesity and oncology.

A key strategic driver for future revenue is the company’s substantial investment in new large?scale production facilities. Bachem has been expanding capacity at its Swiss sites and in the United States to prepare for expected increases in demand for peptide and oligonucleotide APIs, with major projects outlined in capital expenditure plans discussed in the 2024 and 2025 annual reports published in March 2025 and March 2026, respectively, according to Bachem financial reporting as of 03/15/2025. These investments can weigh on near?term profitability but are intended to support higher volumes over the medium term.

Why Bachem Holding AG matters for US investors

Bachem’s relevance for US?focused investors stems from both its customer base and its physical footprint. The company operates manufacturing facilities in the United States and supplies active ingredients to US and global pharmaceutical companies whose products are sold in the American market, according to location information in the corporate profile updated in 2025 on the company website, as summarized in Bachem company profile as of 11/15/2025. As peptide?based therapies gain importance in areas such as obesity and metabolic disease, Bachem’s role as a contract manufacturer can indirectly track US prescription trends.

For international investors who primarily follow US listings, Bachem provides exposure to the life?science tools and pharmaceutical supply chain from a Swiss base, with its shares traded on the SIX Swiss Exchange rather than a US venue. Market participants in the United States can access the stock via cross?border brokerage services that enable trading in Swiss securities, although liquidity and fees may differ from US?listed peers. In this context, developments in exchange rates between the Swiss franc and the US dollar also play a role in how Bachem’s results translate for dollar?based investors, as highlighted in the 2025 annual report discussion of currency effects published in March 2026, according to Bachem financial reporting as of 03/12/2026.

Conclusion

Bachem Holding AG remains a specialized player in the growing field of peptide and oligonucleotide active ingredients, supported by long?standing relationships with global pharma and biotech customers. Its 2025 annual report and recent business updates underline a strategy focused on additional manufacturing capacity and innovation, which may support future revenue but also requires substantial upfront investment. For US?oriented investors, the stock offers internationally diversified exposure to the pharmaceutical supply chain from a Swiss listing, with performance influenced by sector demand, project execution, regulatory requirements and currency movements. As with any individual equity, the risk?return profile depends on factors such as contract visibility, cost discipline and the broader environment for biotech funding and drug development.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.